Omnicell (NASDAQ:OMCL) Stock Price Down 3.7% - Time to Sell?

Omnicell, Inc. (NASDAQ:OMCL - Get Free Report)'s share price was down 3.7% during mid-day trading on Friday . The company traded as low as $46.28 and last traded at $46.65. Approximately 333,258 shares were traded during mid-day trading, a decline of 38% from the average daily volume of 538,703 shares. The stock had previously closed at $48.46.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Wells Fargo & Company upped their price target on shares of Omnicell from $30.00 to $41.00 and gave the stock an "equal weight" rating in a research report on Monday, October 14th. Benchmark reiterated a "buy" rating and set a $48.00 target price on shares of Omnicell in a research report on Wednesday, October 9th. Bank of America reissued a "neutral" rating and issued a $57.00 target price (up from $44.00) on shares of Omnicell in a research note on Thursday, October 31st. StockNews.com downgraded shares of Omnicell from a "buy" rating to a "hold" rating in a research note on Wednesday. Finally, Barclays lifted their target price on shares of Omnicell from $39.00 to $58.00 and gave the stock an "equal weight" rating in a report on Thursday, October 31st. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $52.00.

Omnicell Stock Down 3.9 %

The stock has a market cap of $2.16 billion, a price-to-earnings ratio of -119.46, a PEG ratio of 36.82 and a beta of 0.81. The stock's fifty day moving average is $44.55 and its 200-day moving average is $37.99.

Hedge Funds Weigh In On Omnicell

Institutional investors and hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC lifted its holdings in Omnicell by 248.8% during the second quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company's stock worth $38,000 after acquiring an additional 1,000 shares in the last quarter. GAMMA Investing LLC lifted its stake in Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company's stock valued at $55,000 after buying an additional 553 shares in the last quarter. CWM LLC boosted its holdings in shares of Omnicell by 68.2% in the second quarter. CWM LLC now owns 3,048 shares of the company's stock valued at $83,000 after buying an additional 1,236 shares during the period. 1620 Investment Advisors Inc. increased its position in shares of Omnicell by 230.1% during the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company's stock worth $96,000 after acquiring an additional 1,542 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of Omnicell during the second quarter worth $104,000. Institutional investors and hedge funds own 97.70% of the company's stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.